245% GAIN ON CANCER DETECTION COMPANY GH – ANOTHER 1000% GAIN POTENTIAL – BUYOUT TARGET
By Nigam Arora
245% Gain
Guardant Health (GH) is long from $26.34. It is trading at $91.02 as of this writing, representing a 245% gain.
Buyout Target
GH is a buyout target.
Cancer Screening
Guardant Health is using advanced blood-based liquid biopsy tests and large clinical data sets to transform how cancer is detected, monitored, and treated.
The company’s core business includes its flagship Guardant360 liquid biopsy panel, Guardant Reveal for monitoring minimal residual disease, and early blood based cancer screening test Shield.
Potential Headwinds
Guardant Health is still working toward sustained profitability. It also faces competition from other diagnostics players and large pharma. … Please click here or the title below to read more.
October 31, 2025